Show simple item record

dc.contributor.authorHernández-Díaz, Soniaen_US
dc.contributor.authorMitchell, Allen A.en_US
dc.contributor.authorKelley, Katherine E.en_US
dc.contributor.authorCalafat, Antonia M.en_US
dc.contributor.authorHauser, Russen_US
dc.date.accessioned2012-01-09T15:42:14Z
dc.date.available2012-01-09T15:42:14Z
dc.date.issued2009-02en_US
dc.identifier.citationHernández-Díaz, Sonia, Allen A. Mitchell, Katherine E. Kelley, Antonia M. Calafat, Russ Hauser. "Medications as a Potential Source of Exposure to Phthalates in the U.S. Population" Environmental Health Perspectives 117(2): 185-189. (2008)en_US
dc.identifier.issn1552-9924en_US
dc.identifier.urihttps://hdl.handle.net/2144/2834
dc.description.abstractBACKGROUND. Widespread human exposure to phthalates, some of which are developmental and reproductive toxicants in experimental animals, raises concerns about potential human health risks. Underappreciated sources of exposure include phthalates in the polymers coating some oral medications. OBJECTIVE. The objective of this study was to evaluate whether users of phthalate-containing medications have higher urinary concentrations of phthalate metabolites than do nonusers. METHODS. We used publically available files from the National Health and Nutrition Examination Survey for the years 1999-2004. For certain survey periods, participants were asked to recall use of prescription medication during the past 30 days, and for a subsample of individuals, the urinary concentrations of phthalate metabolites were measured. We a priori identified medications potentially containing phthalates as inactive ingredients and then compared the mean urinary concentration of phthalate metabolites between users and nonusers of those medications. RESULTS: Of the 7,999 persons with information on urinary phthalate concentrations, 6 reported using mesalamine formulations, some of which may include dibutyl phthalate (DBP); the mean urinary concentration of monobutyl phthalate, the main DBP metabolite, among these mesalamine users was 50 times higher than the mean for nonusers (2,257 μg/L vs. 46 μg/L; p < 0.0001). Users of didanosine, omeprazole, and theophylline products, some of which may contain diethyl phthalate (DEP), had mean urinary concentrations of monoethyl phthalate, the main DEP metabolite, significantly higher than the mean for nonusers. CONCLUSION. Select medications might be a source of high exposure to some phthalates, one of which, DBP, shows adverse developmental and reproductive effects in laboratory animals. These results raise concern about potential human health risks, specifically among vulnerable segments of the general population and particularly pregnant women and children.en_US
dc.description.sponsorshipHarvard National Institute of Environmental Health Sciences Center in Environmental Health (ES00002); National Institute for Occupational Safety and Health (OH008578); National Institute of Environmental Health Sciences (ES009718)en_US
dc.language.isoenen_US
dc.publisherNational Institute of Environmental Health Sciencesen_US
dc.subjectCoatingen_US
dc.subjectDidanosineen_US
dc.subjectMedicationsen_US
dc.subjectMesalamineen_US
dc.subjectOmeprazoleen_US
dc.subjectPhthalatesen_US
dc.subjectTheophyllineen_US
dc.titleMedications as a Potential Source of Exposure to Phthalates in the U.S. Populationen_US
dc.typeArticleen_US
dc.identifier.doi10.1289/ehp.11766en_US
dc.identifier.pmid19270786en_US
dc.identifier.pmcid2649218en_US


This item appears in the following Collection(s)

Show simple item record